SCHEMBL279836

SCHEMBL279836

CC(=O)NC1CCN(C(=O)c2cccc(C)c2)C1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.59
HTT P42858 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
ALDH1A1 P00352 2/20 0.55
KMT2A Q03164 2/20 0.55
HPGD P15428 1/20 0.55
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
CYP2C19 P33261 1/20 0.53
CTDSP1 Q9GZU7 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
HSD11B1 P28845 1/20 0.52
MGLL Q99685 1/20 0.52
MAPK1 P28482 1/20 0.50
RHOA P61586 1/20 0.50
MEN1 O00255 1/20 0.49
KDM5A P29375 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22772044 0.91 EPHX2 (0.60) EPHX2HTTL3MBTL1ALDH1A1KMT2A
SCHEMBL16358910 0.85 EPHX1 (0.64) EPHX2L3MBTL1KMT2AMEN1KDM5A
SCHEMBL279835 0.84 KMT2A (0.55) EPHX2ALDH1A1KMT2AHPGDHSD11B1
SCHEMBL12948013 0.84 KMT2A (0.55) EPHX2ALDH1A1KMT2AHPGDHSD11B1
SCHEMBL23417314 0.81 HPGD (0.64) EPHX2HTTL3MBTL1ALDH1A1KMT2A
SCHEMBL23734883 0.80 HTT (0.54) EPHX2HTTL3MBTL1KMT2AHPGD
SCHEMBL22461737 0.80 HTT (0.67) EPHX2HTTL3MBTL1ALDH1A1KMT2A
SCHEMBL22735405 0.80 HTT (0.63) EPHX2HTTL3MBTL1KMT2AHPGD
SCHEMBL14220733 0.80 HTT (0.63) EPHX2HTTL3MBTL1KMT2AHPGD
SCHEMBL19354781 0.79 HTT (0.61) EPHX2HTTL3MBTL1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL EPHX2 2866/4885HTT 1630/4885L3MBTL1 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.